title: Gadolinium contrast may be risky in kidney disease.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Thomson
authors.forename: Tara A
authors.initials: TA
authors.lastname: Collidge
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Mark
authors.forename: Jamie P
authors.initials: JP
authors.lastname: Traynor
mesh_terms: D003287:Contrast Media / Q000009:adverse effects*; D005356:Fibromyalgia / Q000139:chemically induced; D005682:Gadolinium / Q000009:adverse effects*; D019786:Gadolinium DTPA / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D018810:Magnetic Resonance Angiography / Q000592:standards; D009942:Organometallic Compounds / Q000009:adverse effects; D016491:Peripheral Vascular Diseases / Q000175:diagnosis*; D012307:Risk Factors
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C112666:gadoversetamide